Indian biotech giant and world’s largest vaccine maker by volume
The Democratic Republic of Congo has recorded an unprecedented Bundibugyo Ebola outbreak that has spread across six provinces and produced more than 5,000 confirmed cases and over 2,600 deaths. WHO and partners have allocated 70,000 Ervebo vaccine doses—20,000 for a Phase III trial and 50,000 for frontline workers—while CEPI has funded a Bundibugyo-specific vaccine and the US has sent MBP134 treatment vials to Uganda.
A British health worker has been evacuated to a high-level isolation unit in London after testing positive for Ebola linked to the DR Congo outbreak. UK authorities say the public remains at low risk as protocols are activated and treatment proceeds at the Royal Free Hospital.
Vaccine candidates for Bundibugyo virus are entering clinical evaluation as part of the WHO-backed Tumaini program. Trials will assess ChAdOx1 and Moderna’s mRNA-1469 after national approvals, with four vaccination rings in place and initial results expected in early 2027. Treatments under study include MBP134 and remdesivir, with ongoing post-exposure prophylaxis research.